Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana HMO D-SNP MI Prior Auth Policy Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana HMO D-SNP Michigan prior authorization and notification list (PAL)

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization and notification requirements for medications and related services for Humana Dual Integrated HMO Dual Eligible Special Needs Plan (HMO D-SNP) members in Michigan; affects participating providers, facilities, and delegated networks.

    Policy Summary
    PayerHumana
    PolicyHumana HMO D-SNP Michigan prior authorization and notification list (PAL)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate required prior authorization online, by phone (866-461-7273), or by fax (888-447-3430) before providing listed medications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90+medications listed (partial)
    3initiation methods
    90 daysprior auth grace period
    Transplanttransplant contact
    NDC required
    NDC requirement

    Coverage requirements and authorization rules

    Coverage requirements and processes

    Services and medications on this list must follow Medicare coverage guidelines and be medically necessary. Some medications may require step therapy or an advanced coverage determination (ACD).

    Services and medications must follow CMS Medicare coverage guidelines and be medically necessary.

    Authorization pathways

    • Prior authorization may be initiated online via CoverMyMeds.
    • Prior authorization may be initiated by phone at 866-461-7273.
    • Prior authorization may be initiated by fax at 888-447-3430.
    Advanced coverage determinations (ACDs) can be requested for investigational/uncertain services or to confirm payment prior to service.
    Investigational and experimental procedures and devices usually are not covered benefits; consult the patient's Evidence of Coverage or Humana for confirmation.
    Providers should review Humana's Medical and Pharmacy Coverage Policies and the Part B Step Therapy Preferred Drug List when applicable.

    Administrative and billing requirements

    Administrative requirements and billing rules applicable to listed medications.

    Providers must access the fax forms to request prior authorization or provide notification for listed medications as indicated on the PAL.
    When a medication is assigned shared HCPCS or not otherwise classified (NOC) codes (‡), the corresponding National Drug Code (NDC) must be billed on all claims.
    Medications marked with ** require step therapy through a Humana-preferred drug as part of preauthorization; review Humana's Part B Step Therapy PDL for details.
    Entries flagged with †† indicate preauthorization requests that will be reviewed by the Humana National Transplant Network; submission options include fax to 502-508-9300, phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or email transplant@humana.com.

    Coverage / authorization nodes (excerpt)

    Medications listed on the PAL include the generic name, product name, billing codes and special annotations; follow instructions shown on each entry.

    Each medication entry lists generic medication name, product name and billing code(s) (HCPCS/CPT/J/Q codes) when applicable.
    Entries may include symbols that indicate requirements or special handling: * new preauthorization requirement; † new-to-market drug; ‡ shared HCPCS/NOC codes require NDC on claims; ** step therapy required; †† transplant review.
    Many entries include the instruction 'Access the fax forms to request preauthorization or provide notification.' Providers should follow that instruction for submission.

    Prior authorization requirement for listed medications

    Examples of listed medications that require prior authorization or notification; billing codes are shown with each product.

    Providers must request prior authorization or provide notification for listed products such as margetuximab-cmkb (Margenza) — Billing Code = J9353 — by accessing the fax forms as indicated.
    Products shown on the PAL include Mepsevii (vestronidase alfa-vjbk) — Billing Code = J3397; Mircera (methoxy polyethylene glycol - epoetin beta) — Billing Code = J0888; Monjuvi (tafasitamab-cxix) — Billing Code = J9349; Monoferric (ferric derisomaltose) — Billing Code = J1437.
    Providers should follow the PAL entry instructions to access the applicable fax forms to request preauthorization or provide notification for each medication listed.

    Claims/billing and step therapy requirements

    Ancillary claims/billing and step therapy requirements that affect authorization and claims submission.

    All shared HCPCS and not otherwise classified (NOC) codes require a corresponding NDC to be billed on all claims.
    Step therapy may be required through a Humana-preferred drug as part of preauthorization for certain products; affected medications are noted with a step therapy indicator on the PAL.
    Providers should submit all relevant clinical documentation with prior authorization requests to expedite determinations (see documentation requirements in provider actions).

    Medications and billing codes (partial list — segment)

    Segment of listed medications and the billing codes shown on the PAL (partial).

    Examples in this segment include Qivigy (immune globulin IV) — Billing Codes = C9399, J3490, J3590, J1599; Qutenza — Billing Code = J7336; Radicava (edaravone) — Billing Code = J1301; Reblozyl (luspatercept-aamt) — Billing Code = J0896.
    Other entries in this segment include Remicade (infliximab) — Billing Code = J1745; Remodulin (treprostinil injection) — Billing Code = J3285; Ryoncil (remestemcel-L-rknd) — Billing Code = J3402 (†† indicates transplant network review).
    Follow each PAL entry’s submission instruction (e.g., 'Access the fax forms to request preauthorization or provide notification').

    administrative prior authorization requirements (partial)

    Administrative and submission requirements that apply across many PAL entries.

    Symbols legend and recurring notations on the PAL: * new preauthorization requirement; † new-to-market drug; ‡ shared HCPCS/NOC codes require NDC on claims; ** step therapy required through a Humana-preferred drug; †† indicates review by the Humana National Transplant Network.
    Transplant-related preauthorization requests flagged with †† will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone to 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or by email to transplant@humana.com.
    Providers should access and use the listed fax forms to request prior authorization or provide notification for drugs shown on the PAL (examples provided across the list entries).

    Billing codes and NDC requirements

    Representative HCPCS/CPT/J-codes from medication listmixed
    Q2055Abecma billing code (example entry)
    J9264Abraxane billing code (example entry)
    J3262Actemra IV billing code (example entry)
    Additional HCPCS/J-codesmixed
    J1554Asceniv billing code
    J0597Berinert billing code
    examples of J-codes listedmixed
    J9039Blinatumomab (Blincyto)
    J9046Bortezomib
    J9145Daratumumab (Darzalex)
    J9308Ramucirumab (Cyramza)
    J0585OnabotulinumtoxinA (Botox)
    additional J-codesmixed
    J9358fam-trastuzumab deruxtecan-nxki (Enhertu)
    J1302sutimlimab-jome (Enjaymo)
    J0178aflibercept (Eylea)
    Sample medication HCPCS/J-codes from excerptHCPCS
    J1566Immune globulin (Gammagard ERC, Gammagard S/D)
    J1561Immune globulin (Gammaked, Gamunex-C)
    J1557Immune globulin (Gammaplex)
    J9301Obinutuzumab (Gazyva)
    J7326Sodium hyaluronate (Gel-One)
    J7328Sodium hyaluronate (Gelsyn-3)
    J7320Sodium hyaluronate (Genvisc 850)
    J0223Givosiran (Givlaari)
    Selected HCPCS/J/Q codes from medication listmixedCovered
    Q5110filgrastim-aafi (Nivestym)
    J2802romiplostim (Nplate)
    J2182mepolizumab (Nucala)
    J1809fosdenopterin (Nulibry)
    Q5148pegfilgrastim-txid (Nypozi)
    Additional codes present in excerptmixedCovered
    A9607lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
    J9309polatuzumab vedotin-piiq (Polivy)
    J1203cipaglucosidase alfa-atga (Pombiliti)
    Examples of listed HCPCS/J-codes in this segmentHCPCS | CPT | mixed
    C9399Not otherwise classified drugs or biologicals
    J3490Unclassified drugs
    J3590Unclassified biologics
    J1599Unclassified drugs (intravenous immune globulin examples)
    Additional J-codes includedHCPCS | mixed
    J9332Efgartigimod alfa-fcab (IV)
    J9334Efgartigimod alfa and hyaluronidase (Hytrulo)
    J9153Daunorubicin/cytarabine (Vyxeos)
    sample medication billing codes (partial)HCPCS
    J9041bortezomib (Velcade)
    J9376pozelimab-bbfg (Veopoz)
    J1427viltolarsen (Viltepso)
    J1322elosulfase alfa (Vimizim)
    blood-clotting factor billing codes (partial)HCPCS
    J7192antihemophilic factor, human recombinant (e.g., Advate, Kogenate FS, Recombinate listed)
    J7207antihemophilic factor [recombinant] (Adynovate)
    J7210antihemophilic factor (Afstyla)
    J7173concizumab-mtci (Alhemo)
    inv-19: Maximum diagnosis codes per authorization
    Maximum diagnosis codes per authorization6 diagnosis codes may be submitted for a prior authorization request.
    ContextDiagnosis codes are part of required documentation for prior authorization (see documentation requirements).
    Source guidanceSubmit relevant clinical information including HCPCS and diagnosis codes (up to 6) to expedite determination.
    inv-20: NDC requirement for shared/NOTC codes

    How to request authorization and required provider steps

    Prior Authorization

    Prior authorization required — how to submit

    Prior authorization (also called preauthorization or precertification) is required for specified medications delivered in the provider's office, clinic, outpatient or home setting. Prior authorization for medications may be initiated online via CoverMyMeds, by phone at 866-461-7273 (TTY: 711), or by fax to 888-447-3430; request forms are available on Humana's prior authorization for professionally administered drugs website.

    • Online: CoverMyMeds (https://www.covermymeds.health/)
    • Phone: 866-461-7273 (TTY: 711), Mon–Fri 8 a.m. – 11 p.m. Eastern
    • Fax: 888-447-3430 (request forms available on Humana website)
    Denial Risk

    Urgent services and risks of missing authorization

    Urgent or emergent services do not require referrals or prior authorizations; however, failure to obtain required prior authorization for non-urgent services may result in financial penalties to the practice, reduced patient benefits, and possible retrospective medical necessity review.

    Terminology and legend

    inv-42: prior authorization
    DefinitionPrior authorization (also called preauthorization or precertification) is a process requiring the provider to obtain advance approval from the plan to determine whether an item or service will be covered.
    ScopeApplies to specified medications delivered in provider office, clinic, outpatient or home settings listed in the PAL.
    How to initiatePrior authorization may be initiated online (CoverMyMeds), by phone (866-461-7273), or by fax (888-447-3430); ACDs via phone 866-461-7273 or fax 888-447-3430.
    inv-43: step therapy
    DefinitionStep therapy requires trying a Humana-preferred drug(s) before non-preferred medications; details are available on Humana's Part B Step Therapy Preferred Drug List.
    Application
    Policy Summary
    PayerHumana
    PolicyHumana HMO D-SNP Michigan prior authorization and notification list (PAL)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate required prior authorization online, by phone (866-461-7273), or by fax (888-447-3430) before providing listed medications.
    SourceLink
    On This Page
    Coverage requirements and authorization rulesBilling codes and NDC requirementsHow to request authorization and required provider stepsTerminology and legend
    NDC requirement (summary)A corresponding National Drug Code (NDC) must be billed on all claims for shared HCPCS and not otherwise classified (NOC) codes.
    Examples of affected codesShared HCPCS/C9399 and NOC codes such as C9399, J3490, J3590 are subject to the NDC requirement.
    Where statedNoted in the PAL legend and billing/step therapy notes across request instructions.
    inv-21: NDC billing requirement for HCPCS/NOC
    Billing requirementAll shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding National Drug Code to be billed on all claims.
    PurposeEnsures claims identify the specific drug when codes are shared or unclassified.
    Placement in documentStated in the How to request prior authorization legend and general prior authorization rules.
    inv-22: NDC billing requirement for shared HCPCS and NOC codes
    Shared HCPCS + NOC NDC ruleA corresponding NDC must be billed on all claims for shared HCPCS and not otherwise classified codes; this is indicated by the '‡' symbol in the PAL.
    Legend notationThe document legend explains '‡' denotes the NDC billing requirement for shared HCPCS/NOC codes.
    Claim submission impactProviders must include the NDC on claims when using shared or NOC codes to avoid billing issues.
    • Verify benefits and prior authorization requirements with Humana before providing non-urgent services to avoid penalties.
    Documentation Required

    Documentation to include with prior authorization

    Submit all relevant clinical and administrative information with prior authorization requests to expedite determination. Required information may include patient demographics, Humana member ID, date of service, HCPCS and diagnosis codes (up to 6), service location, facility and provider TIN/NPI, caller/requester and attending provider contact, and relevant clinical information.

    • Patient name, date of birth, Humana member ID
    • Date of service or hospital admission
    • HCPCS codes and diagnosis codes (primary and secondary), up to 6
    • Service location (inpatient, outpatient, home, etc.)
    • Facility and provider TIN and NPI, caller/requester name and phone, attending provider phone
    • All relevant clinical information (submit at time of request)
    Prior Authorization

    Transplant preauthorization routing

    Preauthorization requests for transplant-related therapies are reviewed by the Humana National Transplant Network. Submit transplant preauthorization requests by fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. Central), or by email to transplant@humana.com.

    • Fax: 502-508-9300
    • Phone: 866-421-5663, Monday–Friday 7 a.m.–7 p.m. Central
    • Email: transplant@humana.com
    Prior Authorization

    Eculizumab‑aeeb (Bkemv IV) — submission and code

    Eculizumab-aeeb (Bkemv IV) requires prior authorization; the entry lists billing code Q5152 and instructs providers to access the fax forms to request preauthorization or provide notification.

    • Billing code: Q5152
    • Access the fax forms to request preauthorization or provide notification
    Billing Rule

    Belantamab mafodotin (Blenrep) — codes and forms

    Belantamab mafodotin (Blenrep) requires prior authorization/notification and is listed with multiple shared/NOC billing codes; providers should access the fax forms to request preauthorization or provide notification.

    • Billing codes: C9399, J3490, J3590, J9999
    • Shared/NOC codes require corresponding NDC on claims (see billing rules)
    Prior Authorization

    Ciltacabtagene autoleucel (Carvykti) — submission and code

    Ciltacabtagene autoleucel (Carvykti) requires prior authorization; the entry lists billing code Q2056 and directs providers to access the fax forms to request preauthorization or provide notification.

    • Billing code: Q2056
    • Access the fax forms to request preauthorization or provide notification
    Prior Authorization

    Humana National Transplant Network review — overview

    Preauthorization requests for transplant-related therapies will be reviewed by the Humana National Transplant Network; submissions can be made by fax, phone, or email using the contact details and hours provided.

    • Fax/phone/email submission options provided for transplant review (see transplant contact details)
    Prior Authorization

    Transplant preauthorization — submission methods

    Transplant preauthorization requests may be submitted by fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or by email to transplant@humana.com; requests flagged †† will be routed to this network for review.

    • Fax: 502-508-9300
    • Phone: 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. Central)
    • Email: transplant@humana.com
    • †† indicates review by Humana National Transplant Network
    Note

    General preauthorization/notification submission instruction

    For listed medications, providers should 'access the fax forms to request preauthorization or provide notification' as indicated across the list; many entries repeat this instruction and specific request forms are available on Humana's prior authorization website.

    • Use the specific fax forms referenced for each medication when requesting preauthorization or providing notification
    • Request forms are available on Humana's prior authorization for professionally administered drugs website
    Documentation Required

    Legend — special annotations

    Symbols used on the list: * = new preauthorization requirement; † = new-to-market drug addition; ‡ = shared HCPCS/NOC codes require a corresponding NDC billed on all claims; ** = step therapy required through a Humana-preferred drug as part of preauthorization; †† = preauthorization requests reviewed by the Humana National Transplant Network.

    • * New preauthorization requirement
    • † New-to-market drug addition
    • ‡ Shared HCPCS/NOC codes require corresponding NDC on all claims
    • ** Step therapy required through a Humana-preferred drug as part of preauthorization
    • †† Transplant network review
    Prior Authorization

    How to request prior authorization — medication codes and forms

    Access the fax forms to request prior authorization or provide notification for the medications listed; each medication entry includes the associated billing code(s) to include with the request.

    • Include the medication-specific billing code(s) (e.g., J9353, J3397, J0888) with the authorization request
    • Use the fax forms referenced on Humana's prior authorization website
    Prior Authorization

    Transplant preauthorization — submission instructions

    Transplant preauthorization submissions should follow the Humana National Transplant Network routing: fax 502-508-9300, phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or email transplant@humana.com; these methods are repeated throughout transplant-related entries.

    • Fax: 502-508-9300
    • Phone: 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. Central)
    • Email: transplant@humana.com
    Billing Rule

    Billing requirement & step therapy note

    Shared HCPCS codes and 'not otherwise classified' (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims; some medications may also require step therapy through a Humana-preferred drug as part of preauthorization.

    • Ensure corresponding NDC is billed on all claims for shared HCPCS/NOC codes (e.g., C9399, J3490)
    • Medications marked with ** require step therapy through a Humana-preferred drug as part of preauthorization
    Prior Authorization

    Prior authorization request instructions and special notes

    When requesting prior authorization, note the combined instructions and special notes: new preauthorization requirements (*), new-to-market notation (†), NDC billing requirement for HCPCS/NOC codes (‡), step therapy notes (**), and transplant network review/contact details (††).

    • Include medication annotations and follow the corresponding submission path (e.g., †† routes to transplant network)
    Documentation Required

    Preauthorization flags and contact

    Preauthorization flags used on the list: † indicates new-to-market drug; ‡ indicates HCPCS/NOC codes require NDC on claims; ** indicates step therapy required through a Humana-preferred drug; †† indicates review by the Humana National Transplant Network with contact details provided.

    • Follow flag-specific requirements when submitting requests and billing claims
    Note

    General prior authorization instructions and special rules

    All shared HCPCS and not otherwise classified codes require a corresponding NDC to be billed on all claims. Step therapy may be required through a Humana-preferred drug as part of preauthorization, and transplant-related preauthorization requests are reviewed by the Humana National Transplant Network (fax/phone/email provided).

    • Ensure NDC accompanies shared HCPCS/NOC codes on claims
    • Confirm step therapy requirements for medications marked with **
    • Transplant submissions: fax 502-508-9300; phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT); transplant@humana.com
    Prior Authorization

    Fax form access — listed drugs (examples)

    Access the specified fax forms to request prior authorization or provide notification for the listed drugs — examples across the document include Wainua (C9399, J3490), Xeomin (J0588), Xembify (J1558), and Xenpozyme (J0218).

    • Include the listed billing codes with the fax form when submitting requests
    Prior Authorization

    Fax form access — oncology/supportive products

    Access the fax forms to request prior authorization or provide notification for radiolabeled, oncology, and supportive care products; examples include Zevalin (A9543), Zevaskyn (J3389), Ziextenzo (Q5120), Ziihera (J9276), and Zilretta (J3304).

    • Include the product-specific billing code when submitting the fax form
    Medications marked with '**' on the PAL indicate step therapy is required as part of preauthorization.
    Cross-benefit noteSome step therapy strategies may require trials across Medicare Part B and Part D; review the Part B Step Therapy PDL for details.
    inv-44: ‡ (shared HCPCS/NOC codes)
    Symbol meaning (‡)The '‡' symbol indicates HCPCS codes and not otherwise classified codes require a corresponding NDC to be billed on all claims.
    Claim requirementWhen an entry is marked with '‡', include the NDC on all claims for that product when billing shared HCPCS or NOC codes.
    ReferenceExplained in the PAL legend and repeated in multiple 'How to request prior authorization' sections.
    inv-45: ** (step therapy)
    Symbol meaning (**)The '**' symbol denotes that step therapy is required through a Humana-preferred drug as part of preauthorization.
    Action for providersCheck Humana's Part B Step Therapy Preferred Drug List and include evidence of trial of preferred therapy when submitting PA requests for '**' drugs.
    Document locationNoted in the PAL legend and throughout 'How to request prior authorization' entries.
    inv-46: †† (transplant review)
    Symbol meaning (††)The '††' symbol indicates preauthorization requests will be reviewed by the Humana National Transplant Network.
    Submission methodsTransplant PAs can be submitted by fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or by email to transplant@humana.com.
    When usedApplied to transplant-related therapies listed in the PAL; these requests follow the transplant review pathway.
    inv-47: HCPCS codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
    Billing requirement (HCPCS/NOC)HCPCS codes and not otherwise classified (NOC) codes require a corresponding National Drug Code to be billed on all claims for entries marked accordingly.
    Affected code examplesIncludes shared codes such as C9399, J3490 and other NOC entries listed in the PAL.
    DocumentationRefer to the PAL legend and specific line-item instructions when preparing claims.
    inv-48: Step therapy required through a Humana-preferred drug as part of preauthorization.
    Step therapy requirement (summary)Step therapy for some medications must be completed through a Humana-preferred drug as part of preauthorization (indicated by '**').
    Where to find preferred drugsSee Humana's Medicare Part B Step Therapy Preferred Drug List on Humana's provider prior authorization notification lists website.
    Provider optionsIf the practice does not stock the preferred medication, it may be obtained from a pharmacy that can ship to the office; check Humana's specialty and mail-order pharmacy listings.
    inv-49: Preauthorization requests flagged with this symbol will be reviewed by the Humana National Transplant Network.
    Transplant review flagPreauthorization requests flagged with '††' will be reviewed by the Humana National Transplant Network.
    Contact detailsFax: 502-508-9300; Phone: 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT); Email: transplant@humana.com.
    Applicable itemsUsed for transplant-related therapies listed on the PAL that require specialized review.
    inv-50: Shared HCPCS / NOC codes require NDC
    Requirement summaryShared HCPCS and not otherwise classified (NOC) codes require the corresponding NDC to be billed on all claims.
    Notation in PALIndicated by the '‡' symbol in the document legend and repeated in line-item instructions.
    Provider actionInclude NDC on claim submissions for products billed with shared HCPCS or NOC codes to meet billing requirements.
    inv-51: Transplant preauthorization pathway
    Pathway overviewTransplant preauthorization requests are routed to and reviewed by the Humana National Transplant Network for listed transplant-related therapies.
    Submission optionsFax to 502-508-9300; phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT); or email transplant@humana.com.
    ReasonEnsures specialized clinical review for transplant-related therapies and coordination with the transplant network.
    inv-52: Preauthorization notation legend
    Legend overviewSymbols in the PAL: '*' new preauthorization requirement; '†' new-to-market drug; '‡' HCPCS/NOC codes require corresponding NDC; '**' step therapy required; '††' transplant network review.
    How to useRefer to the legend to interpret line-item annotations and follow the related submission or billing instructions.
    Document locationLegend appears in the 'How to request prior authorization' sections across the PAL.
    inv-53: Step therapy required through a Humana-preferred drug as part of preauthorization
    Step therapy indicator'**' indicates that step therapy through a Humana-preferred drug is required as part of preauthorization.
    Provider actionDocument trials of preferred therapy per the Part B Step Therapy PDL when submitting PA requests for '**' medications.
    Reference materialsHumana's Part B Step Therapy Preferred Drug List and coverage policies for criteria details.
    inv-54: Preauthorization requests for transplant-reviewed products will be reviewed by the Humana National Transplant Network; submission options: fax 502-508-9300, phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or email transplant@humana.com
    Transplant review processPreauthorization requests for transplant-reviewed products will be reviewed by the Humana National Transplant Network.
    Submission contactFax: 502-508-9300; Phone: 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT); Email: transplant@humana.com.
    Initiation methodsFollow the transplant network submission options listed in the PAL when requesting preauthorization for flagged items.